Emboldened By Strong Data, Optimer Licenses Antibiotic Candidate To Astellas
Phase III data showing an improved relapse rate relative to the standard of care drove the deal, which could be worth up to $214 million.
Phase III data showing an improved relapse rate relative to the standard of care drove the deal, which could be worth up to $214 million.